http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I666019-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2014-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_718690e92bb0399c85bc3979572ab3da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29acc7e05eacfd7d3a7e2612e206ad8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08c796718b45dbc90ca071abd54543bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4d8a1c2b5b08147b4ce4b355b593e94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb021bfc5cc4ba6214f1daa327c4f1e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a02521f8177d3d9db10b12604c10805b |
| publicationDate | 2019-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-I666019-B |
| titleOfInvention | Dosage therapy of α-iso isomer selective phospholipid 醯 inositol 3-kinase inhibitor |
| abstract | The present invention relates to a method for treating or preventing a proliferative disease in a patient in need, which comprises orally administering a therapeutically effective amount of an α-isomeric selective phospholipid inositol 3-kinase of the formula (I) The inhibitor compound or a pharmaceutically acceptable salt thereof is achieved by at least two consecutive 5-day cycles, wherein the compound is not administered to the patient during a period of about two to three days between the consecutive 5-day cycles The use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament administered according to the dose therapy for the treatment or prevention of a proliferative disease; including the administration of the formula (I) according to the dose therapy Therapeutic treatment of a compound or a pharmaceutically acceptable salt thereof; and related pharmaceutical compositions and packaging. |
| priorityDate | 2013-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 604.